The Merck Group, Amgen, Shionogi and Digital Garage-backed digital cognitive treatment developer will get a Nasdaq Capital Market listing through the deal.

US-based digital therapeutics developer Akili Interactive agreed yesterday to a $1bn reverse merger with special purpose acquisition company Social Capital Suvretta Holdings Corp 1, marking exits for pharmaceutical firms Merck Group, Amgen and Shionogi & Co.

The deal will benefit from $162m in private investment in public equity (PIPE) financing, consisting of $100m from Social Capital and $62m from drug developer PureTech Health, Suvretta Capital Management, Apeiron Investment Group, Temasek, Jazz Venture Partners, Omidyar Technology Ventires and Evidity Health Capital.

…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn